Merck KGaA Drops Lipoprotein(a) Heart Drug After Novartis Trial Failure, Leaving Fewer Drugs in Testing for High Lp(a)

Merck KGaA will not advance its experimental Lp(a)-lowering drug, zerlasiran, after Novartis' similar drug failed to prevent heart attacks or strokes. The decision follows a phase 2 trial where zerlasiran reduced Lp(a) by 80%. Merck is acquiring zerlasiran through its planned purchase of Silence Therapeutics for $1.3 billion. The setback raises doubts about Lp(a)-lowering drugs, with other companies like Amgen and Eli Lilly still testing their candidates.

Original reporting
Published Nov 17, 2026, 5:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 6:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Merck KGaA Drops Lipoprotein(a) Heart Drug After Novartis Trial Failure, Leaving Fewer Drugs in Testing for High Lp(a) — source image
Decision brief

The 30-second read

Low
01

Why it matters

The decision highlights doubts about the Lp(a) therapeutic approach and could pressure other developers in the space.

02

Market read

The news may cause short‑term weakness in Merck KGaA and peer biotech stocks focused on Lp(a) therapies.

03

What to watch

Merck KGaA may redirect resources to other pipelines, mitigating long‑term risk.

Relevance 7/10Novelty 7/10Timing: today

Background

Merck KGaA announced it will not advance its Lp(a)-lowering drug zerlasiran into late‑stage trials after a recent negative outcome for a similar Novartis drug.

Market effects

Potential slowdown in Lp(a) therapeutic pipeline may affect biotech sector sentiment.

European biotech stocks could see modest pressure.

Limited global impact; mainly relevant to investors in cardiovascular drug developers.

Counterpoint

Some investors may view the setback as a buying opportunity if the market overreacts.

Key entities

  • Merck KGaA

    German pharmaceutical company halting development of zerlasiran.

  • Silence Therapeutics

    Target of Merck's acquisition, owner of zerlasiran.

  • Novartis

    Developer of pelacarsen, whose trial failure prompted Merck's decision.

Related articles

$MRKMedAI 8/10

Merck Acquires Rapid Micro Biosystems for Pharma QC Automation

Merck agreed to acquire Rapid Micro Biosystems for $0.75 per share. The deal combines Rapid Micro's automated microbial testing platform with Merck's quality-control portfolio. Merck aims to enhance its pharma QC automation capabilities, while Rapid Micro's CEO sees benefits from broader workflow solutions. The transaction is expected to close in December 2026.

$RPIDMed

Roth/MKM cuts Rapid Micro Biosystems stock rating on Merck deal

Roth/MKM downgraded Rapid Micro Biosystems (RPID) to Neutral, lowering its price target to $0.75 from $3.00. This follows the company's agreement to be acquired by Merck KGaA for $0.75 per share in cash, expected to close in December 2026. The stock has fallen 82% over the past year, with a market cap of $37 million and a weak gross profit margin of 5.5%. The acquisition builds on their existing partnership with MilliporeSigma.

$PFEMed

EU Backs Earlier-Line Moves in Prostate and Kidney Cancer

The European Medicines Agency's CHMP recommended new indications for Pfizer's Talzenna and Merck's Welireg. Talzenna, for prostate cancer, and Welireg, for kidney cancer, could move earlier in treatment if approved by the European Commission. Both drugs showed improved outcomes in clinical trials, with Talzenna reducing progression risk by 52% and Welireg improving progression-free survival.